Core Viewpoint - AbbVie (ABBV.US) reported better-than-expected Q2 results and raised its full-year earnings forecast, driven by newer immunology drugs offsetting the significant decline in sales of its blockbuster arthritis treatment Humira [1] Financial Performance - Q2 revenue reached $15.42 billion, a year-over-year increase of 6.6%, exceeding market expectations by $390 million [1] - Non-GAAP EPS was $2.97, surpassing market expectations by $0.06 [1] - Adjusted Q2 gross margin was 84.4%, and operating margin was 44.3% [1] Product Performance - Global immunology product net revenue was $7.631 billion, with reported baseline growth of 9.5% and operational baseline growth of 9.2% [1] - Humira's net revenue plummeted 58% year-over-year to $1.2 billion, while Skyrizi and Rinvoq generated $4.4 billion and $2 billion in revenue, respectively, with year-over-year growth of approximately 62% and 42% [1] - The neuroscience product portfolio achieved net revenue of $2.7 billion, a year-over-year increase of about 24% [1] - Sales of the leukemia treatment Imbruvica, developed in collaboration with Johnson & Johnson, declined by 10% year-over-year, but the oncology product portfolio's net revenue increased by $1.7 billion, reflecting a year-over-year growth of about 3% [1] Guidance Update - AbbVie raised its adjusted diluted EPS guidance for 2025 from the previous range of $11.67-$11.87 to $11.88-$12.08, with market consensus expectations at $11.98 [1]

每经AI快讯，7月31日，艾伯维盘前股价涨超3%，因其上调财年每股收益指引。 （文章来源：每日经济新闻） ...

格隆汇7月31日｜艾伯维(ABBV.US)预计全年调整后EPS为11.88美元至12.08美元，此前预期为11.67美元 至11.87美元。 ...

智通财经7月31日电，艾伯维盘前股价涨超3%，因其上调财年每股收益指引。 ...

二季度经调整后每股收益2.97美元，上年同期2.65美元。 艾伯维二季度净利润154.2亿美元，预估150亿美元。 ...

生物制药巨头 艾伯维(AbbVie)上调2024财年调整后 每股收益指引至11.88-12.08美元，原预期为11.67- 11.87美元。 ...

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 ABBVIE INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ (Exact name of registrant as specified in its charter) (State or other Jurisdiction (Commission File Number) (IRS Employer Delaware 001-35565 32-0375147 of Incorporation) Identification No.) 1 North Waukegan Road Nor ...

Core Insights - AbbVie reported strong financial results for the second quarter of 2025, with significant growth in its diversified growth platform and pipeline advancements, leading to an increased full-year outlook [2][4][10] Financial Performance - The company achieved second-quarter net revenues of $15.423 billion, reflecting a 6.6% increase on a reported basis and a 6.5% increase on an operational basis [4][5] - Diluted EPS on a GAAP basis was $0.52, a decrease of 32.5%, while adjusted diluted EPS was $2.97, an increase of 12.1% [4][21] - The gross margin for the second quarter was 71.8% on a GAAP basis and 84.4% on an adjusted basis [8] Revenue Breakdown by Portfolio - Immunology portfolio revenues were $7.631 billion, up 9.5% on a reported basis, with Skyrizi and Rinvoq showing significant growth of 62.2% and 41.8%, respectively [4][5][16] - Neuroscience portfolio revenues reached $2.683 billion, an increase of 24.2%, driven by Vraylar and Botox Therapeutic [4][5][16] - Oncology portfolio revenues were $1.676 billion, a modest increase of 2.6%, with Imbruvica experiencing a decline of 9.5% [4][5][16] - Aesthetics portfolio revenues decreased to $1.279 billion, down 8.1%, with Botox Cosmetic and Juvederm also showing declines [4][5][16] Pipeline Developments - AbbVie received FDA approval for Rinvoq as the first oral JAK inhibitor for giant cell arteritis, marking its ninth indication in the U.S. [8] - Positive results were reported from the Phase 3 UP-AA clinical program for Rinvoq in severe alopecia areata, achieving key endpoints [8] - The company announced the acquisition of Capstan Therapeutics, enhancing its capabilities in RNA delivery for cell engineering [8] - Emrelis received accelerated FDA approval for advanced non-small cell lung cancer, expanding AbbVie's oncology treatment options [9] Full-Year Guidance - AbbVie raised its adjusted diluted EPS guidance for 2025 from a range of $11.67 - $11.87 to $11.88 - $12.08, accounting for an unfavorable impact of $0.55 per share related to acquired IPR&D and milestones [10][4]

Group 1 - AbbVie is in talks to acquire Gilgamesh Pharmaceuticals, a company focused on mental health treatments, with a potential valuation of around $1 billion for Gilgamesh [1] - The acquisition discussions follow a selective licensing agreement signed over a year ago between AbbVie and Gilgamesh to co-develop new therapies for mental disorders [1] - Gilgamesh is developing a new generation of psychedelic compounds known as "neuroplastogens" aimed at treating depression, anxiety, substance addiction, and other mental health issues [1] Group 2 - If the acquisition is successful, it will enhance AbbVie's product pipeline in the mental health treatment sector, especially after a previous acquisition related to schizophrenia failed in mid-stage clinical trials [2] - AbbVie currently markets a drug named Vraylar for schizophrenia and bipolar disorder [2] - The potential deal highlights the growing merger and acquisition interest in the mental health treatment field, with Atai Life Sciences also exploring early acquisition interests from major industry players [2] Group 3 - Analysts predict that psychedelic drugs for treating depression may see significant breakthroughs in the next two years, with key trial data expected to be released [2] - Companies like MindMed, Cybin, and Gilgamesh are leading this rapidly evolving field, targeting a large but unmet patient population, with market forecasts predicting sales of approximately $4.5 billion by 2032 [2]

AbbVie is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting growing takeover interest in the sector https://t.co/K18v3XvKoT ...